clinical trial · NCT06939647
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Pulmonary Arterial HypertensionPulmonary Hypertension, Interstitial Lung DiseaseTreprostinil Palmitil
brief summary
The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.
started
—
primary completion
—
completion
—
last updated
Feb 27, 2026
detailed description
Participants will receive TPIP 80 micrograms (μg), 160 μg, or 320 μg, inhalation single-dose capsules, orally, once daily (QD).
official title
Treprostinil Palmitil Inhalation Powder (TPIP) in Patients With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol